US and EU filings for Alexion's Solaris for aHUS
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals has submitted marketing applications to the US FDA and the European Medicines Agency for Soliris (eculizumab), as a treatment for patients with atypical Haemolytic Uremic Syndrome (aHUS).